194a.T
194A.T operates in the healthcare sector, providing pharmaceutical products and related services.
Business. 194A.T operates in the healthcare sector, providing pharmaceutical products and related services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
194A.T operates in the healthcare sector, providing pharmaceutical products and related services.
194A.T maintains a capital structure with a debt-to-equity ratio of 0.93, indicating a moderate reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 0.71, suggesting that it may face challenges in meeting short-term obligations without additional financing. The company's free cash flow of 827,199,000 JPY supports its operational flexibility, although capital expenditures of -116,028,000 JPY indicate ongoing investment in infrastructure.
In terms of profitability, 194A.T reports a return on equity of 21.84% and a return on assets of 9.8%, which are strong indicators of efficient use of equity and assets. These figures suggest that the company is generating substantial returns relative to its equity base and asset base, which is favorable compared to industry norms.
The company's revenue is primarily concentrated in the pharmaceutical segment, with no disclosed geographic diversification in the provided data. This concentration may expose the company to specific market risks, particularly in the healthcare sector, where regulatory changes and competitive pressures can significantly impact revenue streams.
Looking at the growth trajectory, 194A.T's revenue of 5,463,817,000 JPY indicates a stable financial position, but the outlook for the next fiscal year is not explicitly provided in the data. The company's net income of 593,016,000 JPY and operating income of 900,005,000 JPY suggest a healthy profit margin, which is a positive sign for future growth.
The risk assessment for 194A.T highlights a medium liquidity risk, primarily due to a current ratio of 0.71, which may indicate potential difficulties in meeting short-term obligations. The company's dilution risk is assessed as low, with no significant dilution potential reported in the data. However, the company's net cash position is negative after subtracting total debt, which could affect its financial stability.
Recent events and filings for 194A.T are not detailed in the provided data, so no specific recent developments can be cited. The company's financial health and strategic direction are primarily based on the latest financial snapshot and valuation metrics.
- 194A.T has a strong return on equity of 21.84%, indicating efficient use of equity capital.
- The company's liquidity position is medium, with a current ratio of 0.71, suggesting potential short-term financial challenges.
- 194A.T's debt-to-equity ratio of 0.93 indicates a moderate reliance on debt financing.
- The company's free cash flow of 827,199,000 JPY supports operational flexibility and investment in infrastructure.
- The company's revenue is primarily concentrated in the pharmaceutical segment, with no disclosed geographic diversification.
- margin_outlook_rationale: The company's strong return on equity and operating income suggest a positive margin outlook driven by efficient operations.
- rd_outlook_rationale: No specific R&D outlook is provided in the data, but the company's focus on pharmaceuticals implies ongoing investment in research and development.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 194A.T Market data — financials · 2026-05-26